Table 2 Clinical Characteristics, N = 167 (single injection)
N(%) or Median (25th–75th) | |||||
|---|---|---|---|---|---|
All (N = 167) | CHOP (N = 72) | TSRH (N = 95) | P-value* | SMD | |
Joint swelling | |||||
> 1 (vs 0) | 161 (96%) | 69 (96%) | 92 (97%) | 1.00 | 0.05 |
Joint tenderness | |||||
> 1 (vs 0) | 30 (18%) | 27 (38%) | 3 (3%) | < 0.0001 | 0.94 |
Joint range of motion | |||||
> 1 (vs 0) | 95 (57%) | 34 (47%) | 61 (64%) | 0.0281 | 0.35 |
Total joints active | 0.0046 | 0.58 | |||
1 | 90 (54%) | 30 (42%) | 60 (63%) | ||
2 | 58 (35%) | 28 (39%) | 30 (32%) | ||
3 | 13 (8%) | 8 (11%) | 5 (5%) | ||
4 | 4 (2%) | 4 (6%) | 0 | ||
5 | 0 | 0 | 0 | ||
6 | 2 (1%) | 2 (3%) | 0 | ||
2+ Joints Active (vs 1 only) | 77 (46%) | 42 (58%) | 35 (37%) | 0.0058 | 0.44 |
Pain Assessment (1–10)a | 1 (0–4) | 0 (0–4) | 2 (0–4) | 0.0081 | 0.56 |
CHAQ Scoreb | 0.125 (0–0.50) | 0.125 (0–0.125) | 0.125 (0–0.50) | 0.39 | 0.28 |
MD Global Scorec | 1(1–2) | 2 (2–4) | 1 (1–2) | < 0.0001 | 1.80 |
ANA status–Positive | 108 (66%) | 39 (55%) | 69 (74%) | 0.0099 | 0.41 |
RF status– Positive | 4 (3%) | 2 (3%) | 2 (2%) | 1.00 | 0.05 |
HLA-B27 status–Positive | 14 (13%) | 5 (11%) | 9 (14%) | 0.68 | 0.08 |
ESRd | 14 (8–23) | 12 (5–28) | 14 (8–21.5) | 0.48 | 0.14 |
On injection DMARDs | 29 (17%) | 12 (17%) | 17 (18%) | 0.84 | 0.03 |
On injection biologics | 7 (4%) | 6 (8%) | 1 (1%) | 0.0432 | 0.35 |
On NSAIDs | 109 (65%) | 49 (68%) | 60 (63%) | 0.51 | 0.10 |
Total joints injected | 0.0002 | 0.60 | |||
2+ | 53 (32%) | 34 (47%) | 19 (20%) | ||
1 | 114 (68%) | 38 (53%) | 76 (80%) | ||
Steroid injection – Aristopan (vs. Kenalog) | 156 (94%) | 66 (92%) | 90 (96%) | 0.33 | 0.12 |
Knee injection dose (mg) | 10 (2–20) | 10 (2–20) | 10 (2–20) | 0.0132 | 0.40 |
Knee injection dose (mg/kg) | 0.33 (0.10–0.78) | 0.43 (0.13–0.90) | 0.27 (0.10–0.72) | 0.26 | 0.19 |